Kidney Disease Breakthrough Stuns Doctors

A doctor's gloved hand placing red blocks with health symbols on a table

A kidney drug already proven to protect diabetic patients just cleared a major hurdle that could put it in front of millions of people who never had diabetes at all.

Story Snapshot

Finerenone, sold as Kerendia, was originally proven to slow chronic kidney disease progression in patients with type 2 diabetes — a significant but limited population.
The pivotal FIND-CKD phase 3 trial just reported that finerenone also significantly delayed kidney disease progression in patients with non-diabetic chronic kidney disease.
A separate phase 3 trial called FINE-ONE showed finerenone reduces a key marker of kidney damage in people with type 1 diabetes and chronic kidney disease as well.
The broader evidence base is still maturing — the non-diabetic results come from a sponsor announcement, not yet a full peer-reviewed outcomes paper.

What Finerenone Does and Why It Matters

Chronic kidney disease affects roughly one in seven American adults, and for most of its history, the treatment toolkit has been frustratingly thin. Finerenone works by blocking mineralocorticoid receptors — proteins that, when overactivated, drive inflammation and scarring in kidney tissue and blood vessels. Unlike older drugs in its class, finerenone is highly selective, which reduces the side effects that plagued earlier generations of the same type of medication. That selectivity is a large part of why researchers began testing it aggressively across multiple disease populations. ^[5]

The foundational proof came from the FIDELIO-DKD randomized controlled trial published in the New England Journal of Medicine. That trial enrolled patients with chronic kidney disease and type 2 diabetes and found that finerenone produced meaningfully lower risks of kidney disease progression and cardiovascular events compared to placebo. ^[2] Those results were strong enough to earn the drug regulatory approval for that specific population, and they gave researchers the confidence to push into new territory. The cardiovascular protection finding was not a footnote — heart disease kills more chronic kidney disease patients than kidney failure does, which makes a drug that addresses both problems at once genuinely valuable. ^[3]

The Non-Diabetic Expansion Changes the Calculus Entirely

The FIND-CKD trial is the first phase 3 study to test finerenone specifically in patients with chronic kidney disease caused by non-diabetic conditions, including hypertension and other etiologies. ^[1] Bayer announced in early 2026 that the trial met its primary endpoint, with finerenone significantly delaying kidney disease progression versus placebo in that non-diabetic population. ^[6] That is a headline result. Most chronic kidney disease in the world is not diabetic in origin, so expanding the proven benefit to non-diabetic patients would dramatically widen the number of people who could benefit from this drug. The honest caveat is that sponsor top-line announcements precede peer-reviewed publication, and the full data set deserves careful scrutiny before clinicians broadly shift prescribing practice.

The FINE-ONE phase 3 trial added another dimension by showing finerenone reduces urinary albumin-to-creatinine ratio — a standard measure of kidney damage — in people with type 1 diabetes and chronic kidney disease. ^[4] Until now, the drug’s proven base was anchored in type 2 diabetes. Type 1 diabetes is a biologically distinct condition, and demonstrating benefit there closes a gap that had left a meaningful patient group without this option. Taken together, the non-diabetic FIND-CKD results and the type 1 FINE-ONE results suggest finerenone’s mechanism of action is relevant across the kidney disease spectrum in a way that earlier, narrower trials could not confirm.

Why the Surrogate Endpoint Debate Still Matters

Nephrology trials face a structural challenge that other disease areas do not. Hard outcomes — kidney failure, dialysis, death — take years to accumulate because kidney disease progresses slowly. Researchers and regulators therefore rely heavily on surrogate endpoints like estimated glomerular filtration rate slope and albuminuria to infer long-term benefit sooner. ^[1] A meta-analysis of 66 randomized trials found a strong association between treatment effects on kidney filtration rate slope and eventual kidney failure outcomes, which gives those surrogates scientific credibility. ^[1] But surrogate-based conclusions are still inferences, not certainties, and that distinction matters when millions of prescriptions could follow a single trial announcement.

Presented today at #ERA2026, the INFINITY trial found that finerenone reduced the risk of chronic kidney disease progression, including kidney failure alone, and reduced heart failure hospitalisation, cardiovascular death, and all-cause death.

Explore the research:… pic.twitter.com/DzXa6gzMQ1

— The Lancet (@TheLancet) June 5, 2026

The underlying science is coherent, the diabetic evidence base is solid, and the early non-diabetic signals are genuinely encouraging. ^[2]^[6] Rushing to expand prescribing before peer-reviewed full data are published would be premature, but dismissing results from a well-designed phase 3 trial because the announcement came from the sponsor would be equally wrong. The pattern of a drug proving itself in one population and then demonstrating broader applicability is well-established in medicine. Finerenone appears to be following that arc. The next step is publication, independent analysis, and then a regulatory conversation about updated indications. Patients and their physicians should watch that sequence closely.